Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
Abstract PD-L1 expression is an important biomarker for the management of non-small cell lung cancer (NSCLC) but has been highly heterogeneous across studies. We developed a statistical model to reconcile conflicting estimates of PD-L1 prevalence by accounting for between-study variation in test sen...
Saved in:
Main Authors: | Preston Ngo, Wendy A. Cooper, Stephen Wade, Kwun M. Fong, Karen Canfell, Deme Karikios, Marianne Weber |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-80301-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01) -
Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01) -
Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma
by: Lin Zhang, et al.
Published: (2025-01-01) -
The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01) -
Combination of potassium oxonate with anti-PD-1 for the treatment of colorectal cancer
by: Yuanyuan Wang, et al.
Published: (2025-02-01)